L&T SECURES ₹15,000+ CR ULTRA-MEGA OFFSHORE ORDER IN MIDDLE EAST
🌊 L&T Energy Hydrocarbon Offshore has secured an Ultra-Mega order worth over ₹15,000 crore from a prestigious Middle East client.
🏗️ Project involves development of multiple offshore facilities, covering engineering, procurement, construction, installation & commissioning (EPCIC).
🏭 Significant fabrication work will be executed at L&T’s integrated manufacturing and fabrication facilities.
🌍 Order further strengthens L&T’s long-standing presence in the Middle East offshore energy market.
⚡ Management termed it one of the most significant offshore developments currently underway in the Middle East, driven by growing investments to meet future energy demand.
🟢 Impact: Strong Positive — major order boosts L&T’s order book and provides strong long-term revenue visibility.
🌊 L&T Energy Hydrocarbon Offshore has secured an Ultra-Mega order worth over ₹15,000 crore from a prestigious Middle East client.
🏗️ Project involves development of multiple offshore facilities, covering engineering, procurement, construction, installation & commissioning (EPCIC).
🏭 Significant fabrication work will be executed at L&T’s integrated manufacturing and fabrication facilities.
🌍 Order further strengthens L&T’s long-standing presence in the Middle East offshore energy market.
⚡ Management termed it one of the most significant offshore developments currently underway in the Middle East, driven by growing investments to meet future energy demand.
🟢 Impact: Strong Positive — major order boosts L&T’s order book and provides strong long-term revenue visibility.
❤2
TRUALT BIOENERGY TO NDTVProfit (KYC)
India Will Face Sugar Shortage This Year
Won't See Much Impact On Co Operations (On Uneven Monsoon)
Will Be Able To Fund Capex Via Internal Accruals
Don't Have Plans To Raise Funds Right Now
Expect To Increase Capacity Utilisation To 80%
Expect To Get Incentive Package From State Govt
Have Already Received Subsidy From Govt
Will Be Commissioning 9 CBG Plants
CBG Has Been A Big Opportunity For Co
India Will Face Sugar Shortage This Year
Won't See Much Impact On Co Operations (On Uneven Monsoon)
Will Be Able To Fund Capex Via Internal Accruals
Don't Have Plans To Raise Funds Right Now
Expect To Increase Capacity Utilisation To 80%
Expect To Get Incentive Package From State Govt
Have Already Received Subsidy From Govt
Will Be Commissioning 9 CBG Plants
CBG Has Been A Big Opportunity For Co
❤1🍌1
SEBI CHAIRMAN ON CAS
INDICATIVE PRICES ARE EXTREMELY IMPORTANT FOR TRADERS
INCREASED PARTICIPATION WILL IMPROVE CAS
WILL LOOK AT IDENTIFYING PROBLEMS ON THE PMS FRONT FOR CAS
MUTUAL FUNDS NOT FACING ISSUES AROUND CAS
CAS IS A MAJOR STRUCTURAL REFORM
CAS IS SEEING SOME INITIAL TEETHING PROBLEMS
INDICATIVE PRICES ARE EXTREMELY IMPORTANT FOR TRADERS
INCREASED PARTICIPATION WILL IMPROVE CAS
WILL LOOK AT IDENTIFYING PROBLEMS ON THE PMS FRONT FOR CAS
MUTUAL FUNDS NOT FACING ISSUES AROUND CAS
CAS IS A MAJOR STRUCTURAL REFORM
CAS IS SEEING SOME INITIAL TEETHING PROBLEMS
🍌3👍2🖕2
CLEAN MAX ENVIRONMENTAL ENERGY — STAKE SALE UPDATE ⚡
• Approved sale of 26% stake in Clean Max Muoi Pvt Ltd to Relaxo Footwears Ltd for ₹26,000
• Approved sale of 49% stake in Clean Max Chin Pvt Ltd to VVDN Technologies Pvt Ltd for ₹49,000
• Transactions expected to be completed by 30 Oct 2026
• Both subsidiaries were incorporated in June 2026 and have not contributed to financials
• Buyers are not related parties
• Approved sale of 26% stake in Clean Max Muoi Pvt Ltd to Relaxo Footwears Ltd for ₹26,000
• Approved sale of 49% stake in Clean Max Chin Pvt Ltd to VVDN Technologies Pvt Ltd for ₹49,000
• Transactions expected to be completed by 30 Oct 2026
• Both subsidiaries were incorporated in June 2026 and have not contributed to financials
• Buyers are not related parties
STRAIT OF HORMUZ SHIPPING GRINDS TO A HALT AHEAD OF U.S.-IRAN CEASEFIRE EXPIRY
👍1
APOLLO MICRO:
Company has been awarded orders worth INR 80.83 cr by Defence PSUs, State Governments and Private Industries.
Company has been awarded orders worth INR 80.83 cr by Defence PSUs, State Governments and Private Industries.
Bazaar.Update📊
APOLLO MICRO: Company has been awarded orders worth INR 80.83 cr by Defence PSUs, State Governments and Private Industries.
APOLLO MICRO SYSTEMS: ₹80.84 CR ORDER WINS 🚀
• Apollo Micro Systems secures orders worth ₹808.38 Mn (~₹80.84 Cr)
• Orders received from Defence PSUs, State Governments and Private Industries
• Order wins are part of the company’s ordinary course of business
• Apollo Micro Systems secures orders worth ₹808.38 Mn (~₹80.84 Cr)
• Orders received from Defence PSUs, State Governments and Private Industries
• Order wins are part of the company’s ordinary course of business
IRANIAN FOREIGN MINISTRY:
NO TALKS HAVE BEGUN DUE TO WASHINGTON'S VIOLATION OF THE MEMORANDUM OF UNDERSTANDING
NO TALKS HAVE BEGUN DUE TO WASHINGTON'S VIOLATION OF THE MEMORANDUM OF UNDERSTANDING
ICICI SECURITIES — BROKERAGE VIEW 📊
• Brigade Enterprises — BUY | Target ₹885
• GMR Airports — HOLD | Target ₹99 ↑ from ₹93
• Honasa Consumer — BUY | Target ₹720 ↑ from ₹600
• VA Tech Wabag — BUY | Target ₹2,410 ↑ from ₹1,680
• Max Healthcare — BUY | Target ₹1,275 ↑ from ₹1,215
• Page Industries — REDUCE | Target ₹31,500
• Indiqube Spaces — BUY | Target ₹263 | Upside ~42%
Key highlights: Positive stance on Brigade, Honasa, VA Tech Wabag, Max Healthcare & Indiqube; cautious on GMR Airports and Page Industries.
• Brigade Enterprises — BUY | Target ₹885
• GMR Airports — HOLD | Target ₹99 ↑ from ₹93
• Honasa Consumer — BUY | Target ₹720 ↑ from ₹600
• VA Tech Wabag — BUY | Target ₹2,410 ↑ from ₹1,680
• Max Healthcare — BUY | Target ₹1,275 ↑ from ₹1,215
• Page Industries — REDUCE | Target ₹31,500
• Indiqube Spaces — BUY | Target ₹263 | Upside ~42%
Key highlights: Positive stance on Brigade, Honasa, VA Tech Wabag, Max Healthcare & Indiqube; cautious on GMR Airports and Page Industries.
❤1
ANUPAM RASAYAN; CO UPGRADED FY27 REVENUE GROWTH GUIDANCE TO 30 % + FROM 20-25 % EARLIER 🟢🟢
❤1
LUPIN GETS USFDA FINAL APPROVAL FOR PITOLISANT TABLETS
🇺🇸 Lupin receives final approval from the USFDA for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.
💊 The tablets are approved as bioequivalent to Wakix® for the indications covered under the approved labeling.
📋 Approval has been granted for Lupin’s Abbreviated New Drug Application (ANDA).
🎯 The approval allows Lupin to participate in the US market for the Pitolisant generic opportunity.
📈 Adds another approved product to Lupin’s US portfolio and strengthens its presence in complex/specialty generics.
🟢 Impact: Positive — USFDA approval expands Lupin’s US product portfolio and creates a new commercial opportunity.
🇺🇸 Lupin receives final approval from the USFDA for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.
💊 The tablets are approved as bioequivalent to Wakix® for the indications covered under the approved labeling.
📋 Approval has been granted for Lupin’s Abbreviated New Drug Application (ANDA).
🎯 The approval allows Lupin to participate in the US market for the Pitolisant generic opportunity.
📈 Adds another approved product to Lupin’s US portfolio and strengthens its presence in complex/specialty generics.
🟢 Impact: Positive — USFDA approval expands Lupin’s US product portfolio and creates a new commercial opportunity.
❤1
ANAND RATHI ON SUDARSHAN CHEMICAL
BUY | Target: ₹1,450 (Earlier ₹1,350)
Strong Q1 FY27 — Revenue ₹2,640 Cr, +5.4% YoY; adjusted EBITDA at ₹260 Cr.
Heubach margin recovery drives performance; EBITDA at ₹146 Cr with 7.4% margin.
FY27 guidance maintained at ₹9,800–10,200 Cr revenue & ₹800 Cr EBITDA.
FY29 target: ₹12,000–14,000 Cr revenue & ₹1,400–1,500 Cr EBITDA, with net-cash ambition.
Net debt reduced sharply to ₹530 Cr.
Raises FY27E/FY28E EBITDA estimates by 7.5%/2.3% on stronger integration benefits.
Further upside expected from procurement, manufacturing, SAP & SG&A synergies.
Target raised to ₹1,450 from ₹1,350, based on 11.2x FY28E EV/EBITDA.
BUY | Target: ₹1,450 (Earlier ₹1,350)
Strong Q1 FY27 — Revenue ₹2,640 Cr, +5.4% YoY; adjusted EBITDA at ₹260 Cr.
Heubach margin recovery drives performance; EBITDA at ₹146 Cr with 7.4% margin.
FY27 guidance maintained at ₹9,800–10,200 Cr revenue & ₹800 Cr EBITDA.
FY29 target: ₹12,000–14,000 Cr revenue & ₹1,400–1,500 Cr EBITDA, with net-cash ambition.
Net debt reduced sharply to ₹530 Cr.
Raises FY27E/FY28E EBITDA estimates by 7.5%/2.3% on stronger integration benefits.
Further upside expected from procurement, manufacturing, SAP & SG&A synergies.
Target raised to ₹1,450 from ₹1,350, based on 11.2x FY28E EV/EBITDA.
ICICI SECURITIES ON INDIQUBE SPACES
BUY | Target: ₹263 | CMP: ₹185 | Upside: ~42%
Q1 FY27 strong — mature centre occupancy improved 200 bps QoQ to 90%.
Revenue rose 5% QoQ to ₹420 Cr; IGAAP EBITDA up 10% QoQ to ₹80 Cr.
EBITDA margin expanded 81 bps QoQ to 17.7%.
Management expects 1.5–2.0 msf of new operational area during FY27.
ICICI Sec expects 26% revenue CAGR & 31% EBITDA CAGR over FY26–28E.
EBITDA margin seen improving to 18.7% by FY28E, aided by lower rentals and solar power savings.
Operational portfolio projected to expand from 7.8 msf to 11.3 msf by FY28E.
Valuation at 15x Sep’27E EV/EBITDA; key risks are office-leasing slowdown and pricing pressure.
BUY | Target: ₹263 | CMP: ₹185 | Upside: ~42%
Q1 FY27 strong — mature centre occupancy improved 200 bps QoQ to 90%.
Revenue rose 5% QoQ to ₹420 Cr; IGAAP EBITDA up 10% QoQ to ₹80 Cr.
EBITDA margin expanded 81 bps QoQ to 17.7%.
Management expects 1.5–2.0 msf of new operational area during FY27.
ICICI Sec expects 26% revenue CAGR & 31% EBITDA CAGR over FY26–28E.
EBITDA margin seen improving to 18.7% by FY28E, aided by lower rentals and solar power savings.
Operational portfolio projected to expand from 7.8 msf to 11.3 msf by FY28E.
Valuation at 15x Sep’27E EV/EBITDA; key risks are office-leasing slowdown and pricing pressure.
BSE CLEARING LAUNCHES 3-DAY SECURITIES LENDING & BORROWING CONTRACTS
📊 BSE Clearing introduces 3-working-day contracts in the Securities Lending & Borrowing (SLB) segment, effective August 17, 2026.
⏱️ Contracts will have a T+1 first leg and T+3 reverse leg, excluding settlement holidays.
📈 Initially, the shorter-tenor contracts will be available for F&O securities under the “D” series.
🔄 Shorter tenure provides greater flexibility for short-term securities borrowing and delivery requirements.
⚡ The facility could also support inter-exchange arbitrage and better price alignment across trading venues.
🎯 BSE Clearing expects the initiative to improve market efficiency and deepen participation in the SLB ecosystem.
🟢 Impact: Positive — shorter-tenor SLB contracts could boost flexibility, trading activity and participation on BSE’s securities lending platform.
📊 BSE Clearing introduces 3-working-day contracts in the Securities Lending & Borrowing (SLB) segment, effective August 17, 2026.
⏱️ Contracts will have a T+1 first leg and T+3 reverse leg, excluding settlement holidays.
📈 Initially, the shorter-tenor contracts will be available for F&O securities under the “D” series.
🔄 Shorter tenure provides greater flexibility for short-term securities borrowing and delivery requirements.
⚡ The facility could also support inter-exchange arbitrage and better price alignment across trading venues.
🎯 BSE Clearing expects the initiative to improve market efficiency and deepen participation in the SLB ecosystem.
🟢 Impact: Positive — shorter-tenor SLB contracts could boost flexibility, trading activity and participation on BSE’s securities lending platform.
❤1👍1
MUFIN Green Says Employee Base Stands At 350 Now|Diversifying Into Digital Products
Every Integration Takes Almost 6-9 Months
Every Integration Takes Almost 6-9 Months
MUFIN GREEN says In Process To Onboard More Banks |Onboarded 3 Public Sector Banks
INDO AMINES LTD:
TEMPORARY SUSPENSION OF OPERATIONS AT MAHAD FACILITY DUE TO GAS LEAKAGE INCIDENT;
ONE EMPLOYEE FATALITY REPORTED;
COMPANY COOPERATING WITH AUTHORITIES FOR INVESTIGATION AND SAFETY MEASURES.
TEMPORARY SUSPENSION OF OPERATIONS AT MAHAD FACILITY DUE TO GAS LEAKAGE INCIDENT;
ONE EMPLOYEE FATALITY REPORTED;
COMPANY COOPERATING WITH AUTHORITIES FOR INVESTIGATION AND SAFETY MEASURES.
❤1
THYROCARE — PROMOTER PLEDGE FULLY RELEASED 🔓
• Docon Technologies released pledge on 7.95 Cr Thyrocare shares
• Follows full repayment of ₹1,050 Cr NCDs by API Holdings
• Entire promoter shareholding is now pledge-free
• No outstanding pledge or encumbrance remains on promoter shares
• Positive development, reducing promoter pledge-related risk
• Docon Technologies released pledge on 7.95 Cr Thyrocare shares
• Follows full repayment of ₹1,050 Cr NCDs by API Holdings
• Entire promoter shareholding is now pledge-free
• No outstanding pledge or encumbrance remains on promoter shares
• Positive development, reducing promoter pledge-related risk
❤1
PRABHUDAS LILLADHER ON AMBER ENTERPRISES 📊
• BUY | Target ₹9,244 ↑ from ₹8,646
• Q1 FY27 Revenue ₹3,890 Cr, +12.7% YoY | EBITDA ₹310 Cr, +21.6%
• EBITDA margin improved to 8% | Adjusted PAT ₹140 Cr, +39.5%
• Electronics revenue grew 28.5%; Railways order book at ₹2,750 Cr
• FY27 growth guidance maintained; Oppo commercial production expected from Q1 FY28
• BUY maintained with higher target of ₹9,244
• BUY | Target ₹9,244 ↑ from ₹8,646
• Q1 FY27 Revenue ₹3,890 Cr, +12.7% YoY | EBITDA ₹310 Cr, +21.6%
• EBITDA margin improved to 8% | Adjusted PAT ₹140 Cr, +39.5%
• Electronics revenue grew 28.5%; Railways order book at ₹2,750 Cr
• FY27 growth guidance maintained; Oppo commercial production expected from Q1 FY28
• BUY maintained with higher target of ₹9,244
🔥1
CAMPUS ACTIVEWEAR: BOARD APPOINTS MR. RAKESH THAKUR AS CHIEF FINANCIAL OFFICER ; THAKUR BRINGS OVER 22 YEARS OF EXPERIENCE FROM LEADING CO'S INCLUDING BOAT AND HINDUSTAN UNILEVER. GSK HEALTH, PEPSICO & SAMSUNG.
❤1